Work Here?
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$353.3M
Headquarters
Brisbane, California
Founded
2017
Mammoth Biosciences focuses on molecular diagnostics using CRISPR technology to develop tests that quickly and accurately identify ailments, including infectious diseases like COVID-19, at the point of care. This allows for immediate results, reducing delays associated with traditional lab tests. The company differentiates itself with its versatile CRISPR-based detection platform, which offers a wide range of testing applications. Mammoth's goal is to enhance the accessibility and efficiency of diagnostic testing to improve health outcomes.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$353.3M
Above
Industry Average
Funded Over
7 Rounds
Medical, dental, & vision
401(k)
Unlimited vacation
Transportation subsidy
Onsite amenities
Happy hours
Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing
The Nobel Prize is the most prestigious award in the scientific world. It was created according to Mr. Alfred Nobel's will to give a prize “to those who, during the preceding year, have conferred the greatest benefit to humankind” in physics, chemistry, physiology or medicine, literature, and peace. A sixth prize would be later on created for economic sciences by the Swedish central bank.Who to attribute the prize to belongs to multiple Swedish academic institutions.Legacy ConcernsThe decision to create the Nobel Prize came to Alfred Nobel after he read his own obituary, following a mistake by a French newspaper that misunderstood the news of his brother's death. Titled “The Merchant of Death Is Dead”, the French article hammered Nobel for his invention of smokeless explosives, of which dynamite was the most famous one.His inventions were very influential in shaping modern warfare, and Nobel purchased a massive iron and steel mill to turn it into a major armaments manufacturer. As he was first a chemist, engineer, and inventor, Nobel realized that he did not want his legacy to be one of a man remembered to have made a fortune over war and the death of others.Nobel PrizeThese days, Nobel's Fortune is stored in a fund invested to generate income to finance the Nobel Foundation and the gold-plated green gold medal, diploma, and monetary award of 11 million SEK (around $1M) attributed to the winners.Often, the Nobel Prize money is divided between several winners, especially in scientific fields where it is common for 2 or 3 leading figures to contribute together or in parallel to a groundbreaking discovery.Over the years, the Nobel Prize became THE scientific prize, trying to strike a balance between theoretical and very practical discoveries
Company to present preclinical therapeutic data on novel ultracompact CRISPR systemsBRISBANE, Calif.--(BUSINESS WIRE)-- Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR gene-editing platform to create potential one-time curative therapies, today announced that Lucas Harrington, Ph.D., Mammoth’s co-founder and Chief Scientific Officer, will present new preclinical data at the American Society of Gene Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, May 7 - 11, 2024.The oral presentation will describe the optimization of Mammoth’s novel ultracompact CRISPR platform, and its performance in targeting the APOC3 gene, a primary genetic driver of triglyceride metabolism, in humanized mouse models and non-human primates.“Our findings demonstrate the potential of Mammoth’s ultracompact CRISPR systems to deliver in vivo therapies in the liver, beginning with our lead program targeting APOC3, a key factor in familial chylomicronemia syndrome and severe hypertriglyceridemia,” Dr. Harrington said. “We look forward to sharing these data with the scientific community at ASGCT, and to providing future updates as we continue to develop our novel ultracompact nucleases and associated gene-editing technologies to better target tissues beyond the liver and to positively impact the lives of patients living with genetic disease.”Presentation Details. Title: Reduction in Triglycerides through a Novel Ultracompact CRISPR System: Efficacy in Mouse Models and NHP Studies. Abstract #: 15
Seven years after embarking on in vivo therapeutic development using CRISPR/Cas gene-editing technology with Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc. is bringing another company into the collaborative fold. Regeneron will pay Mammoth Biosciences Inc. $100 million, including $95 million as an equity investment, and an up-front payment. Mammoth also could bring in up to $370 million for each target in milestones along with royalties on net sales from products created through the collaboration.
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$353.3M
Headquarters
Brisbane, California
Founded
2017
Find jobs on Simplify and start your career today